Intravenous thrombolytic therapy in myocardial infarction (review)


如何引用文章

全文:

作者简介

I Staroverov

参考

  1. Fletcher A. P., Alkjaersig N., Smyrniotis F. E. et al. The treatment of patients suffering from early MI with massive and prolonged SK therapy. Trans. Assoc. Am. Phys. 1958; 71: 287.
  2. Чазов Е. И., Андреенко Г. В. Экспериментальное обоснование терапии лизируюшими препаратами. В кн.: Совещание по применению антикоагулянтов. Л.; 1961.
  3. Gruppo Italiano per lo Studio della Streptochinasi nelP Infarcts Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
  4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Ibid. 1988; 2: 349-360.
  5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med 1993; 329: 673-682.
  6. Hosai В., Begar S., Wallentin L. et al. A prospective survey of the characteristics, treatment and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur. Heart J. 2002; 15 (1): 1190- 2001.
  7. Widimsky P., Groch L., Zelizko M. et al. Multicenter randomized trial comparing transport to primary angioplasty vs. immediate thrombolysis vs. combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The Prague Study. Ibid. 2000; 21: 823-831.
  8. Andersen H. R. On behalf of the DANAMI-2 trial investigators. Final results of the DANAMI-2 trial. Presented Late breaking clinical trials session at the Annual meeting of the American College of Cardiology, March 2002.
  9. The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N. Engl. J. Med. 1986; 314: 1465-1471.
  10. EMERAS (Estudio Multicentrico Estptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767-772.
  11. The TIMI Study Group Thrombolysis in Myocardial Infarction (TIMI). Trial phase I findings. N. Engl. J. Med. 1985; 312: 932-936.
  12. Neuhaus K. L., Feuerer W., Jeep-Tebble S. et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J. Am. Coll. Cardiol. 1989; 14: 1566-1569.
  13. Cannon С. P., McCabe С. Н., Diver D. J. et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. Ibid. 1994; 24: 1602-1610.
  14. Intravenous NPA for the treatment of infracting myocardial early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur. Heart. J. 2000: 21:2005-2013.
  15. International Joint Efficacy Comparison of Thrombolytics. Randomized, double-blind comparison of reteplase doublebolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. (Published erratum appears in Lancet 1995; 346 (8980): 980). Lancet 1995; 346: 329-336.
  16. The Global Use of Strategies to Open Occluded Coronary Arteries (Gusto III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N. Engl. Med. 1997; 337: 1118-1123.
  17. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Circulation 1998: 98: 2805-2814.
  18. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the safety and efficacy of a new thrombolytic investigators. Lancet 1999; 354: 716-722.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2003

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##